Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.

Abstract

Osteosarcoma is the most common form of primary malignant bone tumor. The use of chemotherapy drugs with many side effects, including high-dose methotrexate, doxorubicin, cisplatin and ifosfamide, has greatly improved osteosarcoma survival compared with surgery alone. However, for 20 years, overall survival remained at a plateau of 60-70% in nonmetastatic disease and 20-30% in metastatic osteosarcoma owing to lung metastases. Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a new agent that improves overall osteosarcoma survival (chemotherapy without L-MTP-PE 70% versus with L-MTP-PE 78%; p = 0.03). L-MTP-PE offers additional benefit for osteosarcoma treatment in combination with chemotherapy, particularly ifosfamide-containing regimens. Clinical experience indicates that side effects such as fever are temporary and controlled or prevented with ibuprofen and/or acetoaminophen premedication; severe side effects are rare. Although surgery will remain the main approach for osteosarcoma treatment of lung metastases, L-MTP-PE combined with other modalities, including chemotherapy, appears to be of benefit in these patients as well.

• Authors: Kanji Mori, Kosei Ando, Dominique Heymann
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 8 Issue 2 Pg. 151-9 (Feb 2008) ISSN: 1744-8328 [Electronic] England
• PMID: 18279055 (Publication Type: Journal Article, Review)

Chemical References

• Liposomes
• Phosphatidylethanolamines
• mifamurtide
• Acetylmuramyl-Alanyl-Isoglutamine

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage, analogs & derivatives)
• Animals
• Bone Neoplasms (mortality, pathology, therapy)
• Clinical Trials, Phase I as Topic
• Disease Models, Animal
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Humans
• Liposomes
• Lung Neoplasms (drug therapy, mortality, secondary)
• Male
• Osteosarcoma (pathology, secondary, therapy)
• Phosphatidylethanolamines (administration & dosage)
• Prognosis
• Survival Analysis
• Treatment Outcome